Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368782 | 0.88 | APLNR (0.36) | GPR119APLNRPOLB | |
| SCHEMBL12662905 | 0.87 | LMNA (0.33) | LMNAMAPK1ALDH1A1 | |
| SCHEMBL22853757 | 0.82 | POLB (0.33) | APLNRPOLB | |
| SCHEMBL102412 | 0.82 | GPR119 (0.38) | GPR119LMNAMAPK1 | |
| SCHEMBL16784817 | 0.81 | ALDH1A1 (0.36) | ALDH1A1KMT2A | |
| SCHEMBL10086734 | 0.80 | GPR119 (0.33) | GPR119APLNRPOLBKMT2A | |
| SCHEMBL12125059 | 0.79 | POLB (0.34) | POLB | |
| SCHEMBL4121215 | 0.79 | GPR119 (0.42) | GPR119KMT2A | |
| SCHEMBL8516141 | 0.78 | GPR119 (0.32) | GPR119LMNAMAPK1 | |
| SCHEMBL25346880 | 0.76 | GPR119 (0.31) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | FUDAN UNIVERSITY (CN) | 2026-05-12 | — | — | US | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | ENODIA THERAPEUTICS SAS (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20040186127-A1 | Novel deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2004-09-23 | — | — | US | disclosed |
| WO-2004063336-A2 | USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS | EISAI CO. LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003057696-A1 | DEAZAPURINES AND USES THEREOF | EISAI CO. LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
| EP-0372817-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4985411-A | Insecticides, Acaricides | THE WELLCOME FOUNDATION LTD. (GB) | 1991-01-15 | — | — | US | disclosed |
| EP-0372817-A1 | Novel heterocyclic pesticidal compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4565767-A | Light-sensitive polymer composition with poly(amic acid), bisazide, and tertiary amine compound | HITACHI, LTD (JP) | 1986-01-21 | — | — | US | disclosed |
| US-4461902-A | BLOOD LIPID AND SUGAR LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | GPR119 3387/4885LMNA 1548/4885MAPK1 1838/4885 |
| US-12624004-B2 | Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof | OPRM1, OPRD1, OPRK1 | GPR119 420/4885LMNA 4332/4885MAPK1 1360/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GPR119 4361/4885LMNA 341/4885MAPK1 4704/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | GPR119 3218/4885LMNA 420/4885MAPK1 1204/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | GPR119 10/4885LMNA 4233/4885MAPK1 2994/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | GPR119 2436/4885LMNA 1073/4885MAPK1 3342/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | GPR119 4574/4885LMNA 793/4885MAPK1 1413/4885 |
| US-20250171434-A1 | SEC61 INHIBITORS AND USE THEREOF | SEC61B, SEC61A1, SEC61G | GPR119 2770/4885LMNA 2999/4885MAPK1 524/4885 |
| US-20040186127-A1 | Novel deazapurines and uses thereof | TPMT, ENTPD5, MTAP | GPR119 1124/4885LMNA 4053/4885MAPK1 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.